Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/9/2023 | Outperform → In-line | Evercore ISI | |
| 11/9/2023 | Buy → Neutral | H.C. Wainwright | |
| 11/9/2023 | $31.00 → $1.00 | Buy → Neutral | Mizuho |
| 7/20/2022 | $8.00 → $3.00 | Neutral → Sell | Citigroup |
| 7/13/2022 | $10.00 | Overweight → Neutral | JP Morgan |
| 7/13/2022 | $16.00 → $5.00 | Buy → Hold | Stifel |
| 5/10/2022 | $15.00 → $8.00 | Buy → Neutral | Citigroup |
| 1/3/2022 | $26.00 → $27.00 | Overweight | JP Morgan |
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
First allogeneic T-Cell therapy BLA offers hope to EBV+ PTLD patients who have limited treatment options and lifespan measured in only a few weeks to months following failure of initial treatment EBV+ PTLD is an ultra-rare, acute, and potentially deadly blood malignancy that occurs after hematopoietic cell transplant (HCT) or solid organ transplant (SOT) when T-cell activity is impaired by immunosuppression Tabelecleucel has a Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026 and would be the first approved therapy in the U.S. for EBV+ PTLD SECAUCUS, N.J., July 24, 2025 /PRNewswire/ -- Pierre Fabre Pharmaceuticals Inc. (PFP) announces the acceptance by U.S. Food a
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplan
Atara Biotherapeutics Resubmits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease to the U.S. FDA Approval of BLA Would Trigger $40 Million Milestone Payment from Pierre Fabre Laboratories Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (EBVALLO™ or tab-cel®) indicated
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2024 financial results after market close on Tuesday, Nov 12, 2024. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the w
Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel®, including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets Atara to Receive Additional Payments of up to USD 640 Million, Significant Double-digit Tiered Royalties as a Percentage of Net Sales, and Funding of Tab-cel Global Development Costs Tab-cel Global Partnership and Associated Strategic Restructuring Extends Atara Cash Runway into Q3 2025 ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication on Track for Early November Atara to Host Conference Call and Webcast today at 6:00 a.m. PDT / 9:00 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA),
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2023 financial results after market close on Tuesday, August 8, 2023. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, At
SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)
SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)
SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)
8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)
SCHEDULE 13D - Atara Biotherapeutics, Inc. (0001604464) (Subject)
Evercore ISI downgraded Atara Biotherapeutics from Outperform to In-line
H.C. Wainwright downgraded Atara Biotherapeutics from Buy to Neutral
Mizuho downgraded Atara Biotherapeutics from Buy to Neutral and set a new price target of $1.00 from $31.00 previously
Experienced, strategic biopharma leader with 40 years of global biopharma experience CDR-Life today announced the appointment of Pascal Touchon, DVM, MBA, to its Board of Directors. Dr. Touchon brings 40 years of international experience in the biopharmaceutical industry, with extensive expertise in oncology and strategic leadership that will further strengthen CDR-Life as it advances its innovative M-gager® platform and pipeline of T cell engager (TCE) therapeutics. "We are delighted to welcome Pascal to our Board of Directors," said Dominik Escher, Ph.D., Chairman of CDR-Life's Board of Directors. "Pascal's remarkable track record in developing and commercializing transformative thera
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company's previously announced $16 million offering that was announced on May 15, 2025. The offering closed on May 16, 2025. Mr. Huang has over 37 years of biotech experience and is the Founder and Managing Partner of Panacea Venture. Prior to Panacea Venture, Mr. Huang was a Managing Partner at Kleiner Perkins (KPCB) China where h
Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J